Annovis Bio completes data cleaning for phase II/III Alzheimer's study; topline data expected April 2024

Annovis Bio, Inc.

Data cleaning completed for phase II/III trial of buntanetap in mild to moderate Alzheimer's disease.
Topline efficacy results expected in April 2024.
Study enrolled 353 patients; 327 completed; three doses (7.5, 15, 30 mg) vs placebo over 12 weeks.
All patients received standard of care in addition to buntanetap or placebo.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.